169 related articles for article (PubMed ID: 38020100)
1. Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study.
Huang D; Yu Y; Lu J; Tan F; Shi Y
Front Med (Lausanne); 2023; 10():1280965. PubMed ID: 38020100
[TBL] [Abstract][Full Text] [Related]
2. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
3. Dose reduction of biologics in patients with plaque psoriasis: a review.
van Riel CAM; Michielsens CAJ; van Muijen ME; van der Schoot LS; van den Reek JMPA; de Jong EMGJ
Front Pharmacol; 2024; 15():1369805. PubMed ID: 38606178
[TBL] [Abstract][Full Text] [Related]
4. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962
[TBL] [Abstract][Full Text] [Related]
5. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
Kridin K; Schonmann Y; Solomon A; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
J Dermatolog Treat; 2022 Jun; 33(4):2014-2020. PubMed ID: 33759683
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
Kridin K; Zirpel H; Mruwat N; Ludwig RJ; Thaci D
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2319-2326. PubMed ID: 37466275
[TBL] [Abstract][Full Text] [Related]
7. A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.
Ye S; Sun H; Xu Z; Xu B; Wu N; Wu J
Immun Inflamm Dis; 2023 Jul; 11(7):e938. PubMed ID: 37506146
[TBL] [Abstract][Full Text] [Related]
8. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.
Liu M; Wang H; Liu L; Cui S; Huo X; Xiao Z; Zhao Y; Wang B; Zhang G; Wang N
Front Immunol; 2022; 13():1046352. PubMed ID: 36389759
[TBL] [Abstract][Full Text] [Related]
9. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A
Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259
[TBL] [Abstract][Full Text] [Related]
10. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry.
Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
J Am Acad Dermatol; 2022 Jan; 86(1):68-76. PubMed ID: 34256035
[TBL] [Abstract][Full Text] [Related]
11. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
12. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
13. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity.
Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
J Dermatolog Treat; 2022 Nov; 33(7):2975-2982. PubMed ID: 35737885
[TBL] [Abstract][Full Text] [Related]
14. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
[TBL] [Abstract][Full Text] [Related]
15. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
16. Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis.
Gisondi P; Geat D; Bellinato F; Girolomoni G
Expert Opin Biol Ther; 2022 Dec; 22(12):1521-1529. PubMed ID: 35930356
[TBL] [Abstract][Full Text] [Related]
17. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Ricardo JW; Lipner SR
Dermatol Ther; 2020 Sep; 33(5):e13687. PubMed ID: 32458536
[TBL] [Abstract][Full Text] [Related]
18. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
19. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Leung YY; Korotaeva TV; Candia L; Pedersen SJ; Bautista Molano W; Ruderman EM; Bisoendial R; Perez-Alamino R; Olsder W; Möller B; Grazio S; Gudu T; Mody GM; Pineda C; Raffayova H; Rohekar S; Goldenstein-Schainberg C; Gutierrez Urena SR; Casasola Vargas JC; Meghnathi B; Prasad R; Richette P; Miranda JRS; Malliotis N; Lindqvist U; Simon D; Ezeonyeji A; Soriano ER; FitzGerald O
J Rheumatol; 2023 Jan; 50(1):119-130. PubMed ID: 36243409
[TBL] [Abstract][Full Text] [Related]
20. Immunological Effects of Anti‒IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida Infections.
Bruno M; Davidson L; Koenen HJPM; van den Reek JMPA; van Cranenbroek B; de Jong EMGJ; van de Veerdonk FL; Kullberg BJ; Netea MG
J Invest Dermatol; 2022 Nov; 142(11):2929-2939.e8. PubMed ID: 35662644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
